Minimal Residual Disease (MRD) Analysis: T ALL

Detection of minimal residual disease in Acute Lymphoblastic Leukemia predicts outcome. This assay helps to identify patients at higher/lower risk of relapse. Detection of minimal residual disease is important for risk assessment and stratification of therapy. It detects sub microscopic levels of leukemia with a clinical sensitivity of 0.01%.

  • Test Type:
  • Pre-test Information:
    MANDATORY REQUIREMENTS: i) Sample time point (time of chemotherapy). ii) Previous immunophenotype report. iii) Clinical History and original TRF. iv) Date and time when sample was drawn to be mentioned on the TRF. All information should be given at the time of registration/before the sample is processed.
  • Report Delivery:
    Sample Daily by 9 am; Report third working day.
  • Components:

Sample Report